Clinical trials: Cytarabine
- Drug or intervention Cytarabine
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
- Trial name
- NCT02626338
- Testing
- Crenolanib, Mitoxantrone, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Acute Myelogenous Leukemia
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute or refractory lymphoblastic leukemia (ALL) who have had at least 2 prior…
- Trial name
- NCT00317642
- Testing
- clofarabine (IV formulation), cytarabine
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 326 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Myeloid Leukemia
Alvocidib Biomarker-driven Phase 2 AML Study
The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) of ACM (Alvocidib/Cytarabine/Mitoxantrone) compared to CM (Cytarabine/Mitoxantrone) treatment in refractory or relapsed AML…
- Trial name
- NCT02520011
- Testing
- Alvocidib, Cytarabine, Mitoxantrone
- Where
- 38 sites in United States, Canada and 2 more
- Volunteers
- 104 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Myelogenous Leukemia
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase.
- Trial name
- NCT00333840
- Testing
- imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C)
- Where
- 163 sites in United States, Australia and 14 more
- Volunteers
- 1,106 people
- Sponsor
- Novartis Pharmaceuticals
Myeloid Malignancies
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).
- Trial name
- NCT04778410
- Testing
- Magrolimab, Azacitidine, Venetoclax
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 54 people
- Sponsor
- Gilead Sciences
Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
This study will assess the safety and efficacy of vismodegib in patients with relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS).
- Trial name
- NCT01880437
- Testing
- cytarabine, vismodegib
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Newly Diagnosed AML With FLT3 Activating Mutations
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3…
- Trial name
- NCT02283177
- Testing
- crenolanib, cytarabine, daunorubicin
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Acute Myeloid Leukemia
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A study is designed to assess if BL-8040 in combination with cytarabine (Ara-C) can help controlling the disease in patients with Acute Myeloid Leukemia (AML) that have relapsed or did not respond adequately to previous…
- Trial name
- NCT01838395
- Testing
- Ara-C, BL-8040
- Where
- 10 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- BioLineRx, Ltd.
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Trial name
- NCT04029688
- Testing
- Idasanutlin, Venetoclax, Cyclophosphamide
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Myeloid, Acute
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
- Trial name
- NCT02348489
- Testing
- SGI-110 (guadecitabine), Treatment Choice
- Where
- 135 sites in United States, Australia and 22 more
- Volunteers
- 815 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
The purpose of this Phase I study is to determine the safety and tolerability including the maximum dose (MTD) and dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by…
- Trial name
- NCT03298984
- Testing
- Alvocidib, Cytarabine, Daunorubicin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sumitomo Pharma America, Inc.
Acute Myeloid Leukemia
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC.
- Trial name
- NCT02920008
- Testing
- guadecitabine, Treatment Choice (TC)
- Where
- 95 sites in United States, Belgium and 13 more
- Volunteers
- 302 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia
Trial of Decitabine in Patients With Acute Myeloid Leukemia
The purpose of this study is to compare the results in older patients who have newly diagnosed or secondary acute myeloid leukemia (AML) and who are to either receive decitabine or patient's choice with the physician's advice of…
- Trial name
- NCT00260832
- Testing
- Cytarabine or Supportive Care, Dacogen (decitabine) only
- Where
- 108 sites in United States, Australia and 13 more
- Volunteers
- 485 people
- Sponsor
- Eisai Inc.
Relapsed/Refractory Acute Myeloid Leukemia
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
A Phase III study to evaluate the safety and efficacy of CPI-613® (devimistat) in combination with High Dose Cytarabine and Mitoxantrone in comparison with high dose Cytarabine and Mitoxantrone and control sub-groups: combination…
- Trial name
- NCT03504410
- Testing
- CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine
- Where
- 60 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Cornerstone Pharmaceuticals
Solid Tumors
Study of INCB053914 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation study of the proviral integration site of Moloney murine leukemia virus (PIM) kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 4 parts.
- Trial name
- NCT02587598
- Testing
- INCB053914, I-DAC (Intermediate dose cytarabine), Azacitidine
- Where
- 19 sites in United States
- Volunteers
- 97 people
- Sponsor
- Incyte Corporation
Acute Myeloid Leukemia (AML)
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
The purpose of this study is to evaluate the efficacy, safety and tolerability of ibrutinib alone or in combination with either cytarabine or azacitidine in the treatment of subjects with Acute Myeloid Leukemia (AML) who have…
- Trial name
- NCT02351037
- Testing
- Ibrutinib, Ibrutinib + LD-AraC, Ibrutinib+Azacitidine
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pharmacyclics LLC.
High Risk Acute Myeloid Leukemia
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
- Trial name
- 301 (NCT01696084)
- Testing
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Where
- 43 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Jazz Pharmaceuticals
Leukemia, Myeloid, Acute
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a multicenter, double-blind, randomized, placebo-controlled study designed to compare overall survival in participants with relapsed or refractory AML treated with idasanutlin in combination with cytarabine versus…
- Trial name
- MIRROS (NCT02545283)
- Testing
- Cytarabine, Idasanutlin
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 447 people
- Sponsor
- Hoffmann-La Roche
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL)
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
This study is about an anticancer drug called ponatinib which is a tyrosine kinase inhibitor given with chemotherapy to children, teenagers, and young adults up to 21 years of age with Philadelphia Chromosome-Positive Acute…
- Conditions
- Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
- Trial name
- NCT04501614
- Testing
- Ponatinib, Chemotherapy Agents
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 11 people
- Sponsor
- Takeda
Leukemia, Myeloid, Acute
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
The trial will be performed in two parts, a phase I part and a phase IIa part. In the phase I part of the trial, BI 6727 will be investigated as monotherapy and in combination with low dose cytarabine (LD-Ara-C) in patients with…
- Trial name
- NCT00804856
- Testing
- Volasertib, Cytarabine
- Where
- 27 sites in Austria, Belgium and 5 more
- Volunteers
- 180 people
- Sponsor
- Boehringer Ingelheim